Related Experiment Video
Updated: Jul 19, 2026
A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Mitral valve surgery in non-ischemic cardiomyopathy
1Division of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Insights
Dilated cardiomyopathy can cause heart failure, often worsened by mitral valve regurgitation. Surgical intervention for this condition in dilated cardiomyopathy patients shows promising short-term survival rates but requires careful management.
Area of Science:
- Cardiology
- Cardiac Surgery
- Heart Failure Research
Background:
- Dilated cardiomyopathy involves myocyte cytoskeletal weakness, leading to ventricular dilatation and heart failure.
- Functional mitral valve regurgitation affects up to 40% of heart failure patients with dilated cardiomyopathy, creating a detrimental cycle.
- Advanced valvular heart disease is a significant cause of non-ischemic cardiomyopathy.
Purpose of the Study:
- To evaluate the efficacy and outcomes of surgical management for mitral valve regurgitation in patients with non-ischemic dilated cardiomyopathy.
- To assess the risks and benefits of mitral valve repair versus replacement in this patient population.
- To compare the clinical outcomes of mitral valve surgery with cardiac transplantation.
Main Methods:
- Retrospective analysis of 43 patients with non-ischemic cardiomyopathy undergoing mitral valve repair or replacement between 1993 and 2002.
- Vigorous medical management and judicious perioperative care protocols.
- Long-term survival analysis, including 1-, 3-, and 5-year survivorship rates for mitral valve repair.
Main Results:
- Mortality for mitral valve repair or replacement was 2.3% in the studied cohort.
- Early-to-intermediate term clinical outcomes of mitral valve surgery compared favorably with cardiac transplantation.
- 1-, 3-, and 5-year survivorships after mitral valve repair were 84%, 80%, and 33%, respectively.
Conclusions:
- Surgical management of mitral valve regurgitation in dilated cardiomyopathy, when combined with optimal medical care, can be performed with acceptable operative risk.
- While early outcomes are encouraging, long-term results of mitral valve surgery in this condition are less satisfactory.
- Future research into novel therapies like cell transplantation holds potential for improving the management of dilated cardiomyopathy.
Abstract:
Dilated cardiomyopathy is a disorder of the cardiac muscle in which myocyte cytoskeletal weakness leads to ventricular dilatation and congestive cardiac failure. Most commonly, the etiology of non-ischemic cardiomyopathy is unknown (idiopathic) and, in our practice, the second most common cause is advanced valvular heart disease. Functional mitral valve regurgitation occurs in up to 40% of patients with heart failure due to dilated cardiomyopathy and contributes to a vicious cycle of volume overload, further left ventricular dilatation, and worsening mitral valve regurgitation and heart failure. Surgical management of mitral valve regurgitation in dilated cardiomyopathy may carry a high risk and can be very challenging. However, operative risk is mitigated by continued vigorous medical management and judicious perioperative care. For example, at our Clinic, mortality for mitral valve repair or replacement in 43 patients with non-ischemic cardiomyopathy having operation between 1993 and 2002 was 2.3%. Additional procedures to reverse cardiac remodeling have not proven to be uniformly successful and continue to undergo scientific scrutiny. Clinical outcome of mitral valve surgery in non-ischemic dilated cardiomyopathy compares well with cardiac transplantation in the early-to-intermediate term, but the long-term results are less satisfactory. For our patients having mitral valve repair, the 1-, 3-, and 5-year survivorships were 84%, 80% and 33%. Evolving technology and research that focus on methods of altering or reversing cardiomyopathy; e.g., cell transplant, may have significant impact on the future management of this debilitating illness.
Related Concept Videos
01:25Mitral Regurgitation III: Medical Management
01:22Mitral Stenosis I: Introduction
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
01:26Mitral Stenosis III: Medical Management
01:27Mitral Stenosis IV: Nursing Management
01:29Cardiomyopathy V: Interprofessional Care